6875.TWO Pharmosa Biopharm Inc.

Healthcare Biotechnology Taiwan OTC Exchange
25.20 TWD
Close of Nov 5, 2026
24.70 58.70
Market cap
TWD 3.26B
P/E
-
P/B
2.48x
ROE
-28.4%
Dividend yield
-
Fundamental score
-

Ratios use the latest price and the current fiscal year annualized from 2 quarters up to Jun 2026.

Is 6875.TWO undervalued?

Graham number

The Graham number of Pharmosa Biopharm Inc. cannot be estimated reliably (it needs positive earnings and book value).

Graham number = √(22.5 × EPS × book value per share): the most a defensive investor should pay according to Benjamin Graham. An estimate, not a recommendation to buy or sell. How is it calculated?

Pharmosa Biopharm Inc. fundamental analysis

No fundamental analysis for Pharmosa Biopharm Inc. yet.

Pharmosa Biopharm Inc. stock price

Prices on the chart can differ slightly from the closing prices StockSummer uses for its ratios.

About Pharmosa Biopharm Inc.

Pharmosa Biopharm Inc., a biotechnology company, focuses on research and development of new drugs in Taiwan. The company develops L606, an inhalation/device combination for the treatment of pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease; and L608, an inhalation/device combination for the treatment of pulmonary vascular disease, which has completed a Phase I clinical trial. The company was formerly known as Pharmosa Limite…

Full company profile